low - Clinical-stage biotech operations are largely insulated from GDP fluctuations as R&D spending is committed years in advance and trial timelines are regulatory-driven, not economically driven. However, the company's ability to raise capital is highly sensitive to risk appetite in biotech equity markets, which correlates with broader economic conditions and tech/growth stock sentiment.

High interest rates negatively impact Tonix through two channels: (1) Valuation compression - biotech DCF models discount future cash flows at higher rates, disproportionately affecting pre-revenue companies with cash flows 5-10 years out; (2) Capital availability - rising rates reduce investor appetite for speculative, cash-burning growth stocks as safer fixed-income alternatives become attractive. The company's 9.89x current ratio provides temporary insulation, but sustained high rates make future equity raises more dilutive.

momentum/speculative - Attracts high-risk biotech traders seeking 3-10x returns on binary clinical catalysts, not fundamental value investors. The -70.3% six-month return followed by +39.2% one-year return shows extreme volatility typical of clinical-stage names. With no revenue, negative margins, and total dependence on trial outcomes, this is pure speculation on FDA approval probability. Institutional ownership is likely minimal given market cap and risk profile.